Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8752W HIGH $3.19
Volume
677.14 K
Value Traded
283.22 K
Short % Float
4.09%
-3.36%Week
-13.53%1 Month
-20.14%3 Month
-10.16%6 Month
-68.78%5 Year
-68.78%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
69.96 M
EPS (TTM)
-0.44
P/E Ratio
-
Ent. Value
42.36 M
Total Shares
60.81 M
Float Shares
51.26 M
Insiders
16.98%
Institutions
22.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MAIA Catalyst Timeline
Dated clinical, regulatory and corporate events for MAIA Biotechnology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MAIA Biotechnology, Inc.
238Total events
18Upcoming
56Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment MilestoneateganosineTrial
65 patients enrolled in pivotal THIO-104 Phase 3 trial, 65% of 100-patient target
non-small cell lung cancersource ↗
▲Enrollment CompleteateganosineTrial
Enrollment completed in Part C of THIO-101 Phase 2 study
non-small cell lung cancersource ↗
▲Trial Authorization (CTA / IND)ateganosineEx-US Regulatory
AEMPS and INFARMED approve THIO-104 trial expansion into Spain and Portugal
non-small cell lung cancer (NSCLC)source ↗
●Enrollment UpdateateganosineTrial
THIO-104 has enrolled 65 NSCLC patients across 28 European sites and 10 Taiwan sites
non-small cell lung cancer (NSCLC)source ↗
▲Trial Authorization (CTA / IND)ateganosineEx-US Regulatory
AEMPS and INFARMED approve THIO-104 trial expansion into Spain and Portugal
non-small cell lung cancersource ↗
●Enrollment UpdateateganosineTrial
THIO-104 has enrolled 65 NSCLC patients across 28 European sites and 10 Taiwan sites
non-small cell lung cancersource ↗
▲Enrollment UpdateateganosineTrial
THIO-104 Phase 3 enrollment reaches 65 randomized patients
advanced non-small cell lung cancer (NSCLC)source ↗
▲First Patient DosedateganosineTrial
First U.S. patient dosed in Phase 2 THIO-101 expansion in 3L NSCLC
third-line non-small cell lung cancer (NSCLC)source ↗
▲Quarterly UpdateCorporate
CEO Vlad Vitoc acquires 73,000 MAIA shares in open market purchase
▲Enrollment UpdateTrial
Board member Ramiro Guerrero acquires 185,078 MAIA shares in open market purchases
●Oral PresentationPresentation
Oral presentation of novel divalent cancer RedOx activatable nucleoside prodrugs at IRT 2026
cancersource ↗
●Poster PresentationPresentation
Poster presentation of new telomere-targeting dual-pharmacophore dinucleotide prodrugs at IRT 2026
cancersource ↗
▲Preclinical PoCPreclinical
Next-generation divalent telomere-targeting candidates show increased anticancer activity in preclinical models
cancersource ↗
▲Topline ReadoutategansineClinical Data
Initial Part C efficacy data: 90.5% DCR in third-line NSCLC
non-small cell lung cancersource ↗
▲Enrollment CompleteategansineTrial
Completed international enrollment in Part C of THIO-101
non-small cell lung cancersource ↗
▲Additional DataateganosineClinical Data
Positive initial efficacy data from Phase 2 THIO-101 Part C expansion: DCR 90.5%
third-line non-small cell lung cancer (NSCLC)source ↗
▲Topline ReadoutateganosineClinical Data
Positive initial efficacy data from Phase 2 THIO-101 Part C expansion: DCR of 90.5%
third-line non-small cell lung cancer (NSCLC)source ↗
▲Enrollment CompleteateganosineTrial
Phase 3 trial enrollment completion
non-small cell lung cancersource ↗
▲Enrollment CompleteategansineTrial
Completed international enrollment in Part C of THIO-101
non-small cell lung cancersource ↗
▲Enrollment CompleteategansineTrial
Completed international enrollment in Part C of Phase 2 THIO-101 expansion trial
non-small cell lung cancersource ↗
▲Enrollment UpdateateganosineTrial
Third U.S. clinical site (Winship Cancer Institute) activated and enrolling patients for Phase 2 expansion trial
non-small cell lung cancer (NSCLC)source ↗
▲Trial InitiationategenosineTrial
Phase 3 pivotal trial screening and enrollment ongoing
non-small cell lung cancer (NSCLC)source ↗
▲Enrollment UpdateategansineTrial
29 patients dosed among 34 activated trial sites in 6 foreign countries
non-small cell lung cancersource ↗
▲IND ClearanceategenosineIND
FDA cleared IND amendment to open U.S. enrollment for Phase 2 THIO-101 trial expansion
advanced non-small cell lung cancer (NSCLC)source ↗
◆Trial InitiationategenosineTrial
Phase 3 THIO-104 trial actively screening and enrolling patients
advanced non-small cell lung cancer (NSCLC)source ↗
◆Enrollment UpdateategenosineTrial
Second U.S. clinical site expected to activate in coming weeks
advanced non-small cell lung cancer (NSCLC)source ↗
●Poster PresentationateganosinePresentation
Trial in Progress poster for THIO-104 at ASCO 2026
non-small cell lung cancersource ↗
▲First Patient DosedateganosineTrial
First U.S. site activated for Phase 2 THIO-101 expansion trial
advanced non-small cell lung cancer (NSCLC)source ↗
●Enrollment UpdateateganosineTrial
44 active sites in 6 countries for THIO-101 expansion trial
advanced non-small cell lung cancer (NSCLC)source ↗
◆Topline ReadoutateganosineClinical Data
Phase 2 expansion trial topline data
non-small cell lung cancersource ↗
◆Topline ReadoutategansineClinical Data
Topline data from Phase 2 expansion trial
non-small cell lung cancer (NSCLC)source ↗
▲Enrollment CompleteategansineTrial
Phase 3 trial enrollment completion
non-small cell lung cancer (NSCLC)source ↗
◆Enrollment UpdateateganosineTrial
Part C expansion currently enrolling up to 48 participants in Asia and Europe
non-small cell lung cancersource ↗
▲Poster PresentationateganosinePresentation
Poster presented at ELCC 2026 on OS data from THIO-101 Parts A and B
non-small cell lung cancersource ↗
▲Topline ReadoutateganosineClinical Data
Overall survival exceeding two years for eight patients in Parts A and B
non-small cell lung cancersource ↗
▼Equity OfferingCorporate
Closing of $30 million underwritten public offering of common stock
▼Equity OfferingCorporate
Proposed underwritten public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Private placement of 1,233,488 shares at $1.224 per share with warrants
▲First Patient DosedateganosineTrial
First patient dosed in THIO-104 Phase 3 pivotal trial of ateganosine sequenced with checkpoint inhibitor as third-line treatment for advanced NSCLC
advanced non-small cell lung cancersource ↗
▲Trial InitiationateganosineTrial
THIO-104 Phase 3 trial initiated with screening and enrollment underway
advanced non-small cell lung cancersource ↗
▲Fast Track DesignationateganosineDesignation
FDA Fast Track Designation for ateganosine in NSCLC
non-small cell lung cancer (NSCLC) resistant to immunotherapy and chemotherapysource ↗
▲Trial InitiationateganosineTrial
Initiating Phase 3 THIO-104 trial
non-small cell lung cancer (NSCLC)source ↗
▲First Patient DosedateganosineTrial
First patient dosed in pivotal THIO-104 Phase 3 trial
non-small cell lung cancersource ↗
◆Trial InitiationateganosineTrial
Expect to begin enrolling patients in HCC trial by end of 2025
hepatocellular carcinomasource ↗
▲Quarterly UpdateCorporate
CEO and board members purchased approximately 182,445 shares between November 21 and 28, 2025
▲Enrollment UpdateategansineTrial
Enrollment started in Romania for Phase 2 THIO-101 Part C study
advanced non-small cell lung cancersource ↗
●Oral PresentationategansinePresentation
CEO presented telomere targeting efficacy at Smart Diaspora 2025 conference
non-small cell lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How MAIA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | THIO-101 (THIO, 6-thio-dG) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$81M
Pipeline Value
Fair Value
Valuation Signal
1
Drugs Scored
1.1x
rNPV / MCap
Top 48%
Micro Cap(rank 316 of 658)
Percentile Rank
MAIA Biotechnology, Inc. faces pipeline headwinds (37/100), with $1.2B risk-adjusted pipeline value, led by 6-Thio-2'-Deoxyguanosine in Carcinoma, Non-Small-Cell Lung (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6-Thio-2'-Deoxyguanosine Small moleculeNCT05208944 | Carcinoma, Non-Small-Cell Lung | Phase 3 | ACTIVE NOT_RECRUITING | 527 | Dec 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every MAIA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Vitoc VladDirector, Officer (Chief Executive Officer), 10% Owner | Buy | 73,000 1,049,121 held | $1.37 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MAIA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MAIA for Q2 2026. | ||||
MAIA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MAIA ranks across every disease it competes in
Competitive Position is a premium feature
See how MAIA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMAIA News
MAIA▼ -2.5%today
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
MAIA Biotechnology has successfully completed patient enrollment in Part C of its Phase 2 trial and reached 65% of its enrollment target for the pivotal Phase 3 trial for ateganosine in treating non-small cell lung cancer. The Phase 2 trial has reported a 90.5% interim disease control rate, indicating strong efficacy. The FDA has granted Fast Track designation for ateganosine, which could expedite its review process.
Read more →MAIAMAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
MAIA Biotechnology has received regulatory approval to expand its pivotal Phase 3 THIO-104 clinical trial for non-small cell lung cancer into Spain and Portugal. This expansion aims to provide access to investigational therapies for patients in regions with high lung cancer incidence. The company plans to enroll 100 patients by the end of 2026 and expects interim survival data by 2027.
Read more →MAIAMAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology has reported significant progress in its pivotal Phase 3 trial for ateganosine, a novel telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). With 65 patients enrolled and a 90.5% disease control rate observed, the company aims to exceed 100 patients by year-end. The FDA has granted Fast Track designation for ateganosine, enhancing its regulatory pathway.
Read more →MAIAMAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
MAIA Biotechnology has successfully dosed the first U.S. patient in its Phase 2 clinical trial for ateganosine, targeting non-small cell lung cancer. This milestone follows FDA clearance of their amended IND submission and is supported by a $2.3 million NIH grant. The trial aims to evaluate ateganosine's efficacy in patients who have not responded to previous treatments.
Read more →MAIAMAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
MAIA Biotechnology has announced significant stock purchases by its CEO and a board member, indicating strong confidence in the company's future. The purchases totaled approximately $252,284 and were made as MAIA progresses in its pivotal Phase 3 trial for ateganosine in non-small cell lung cancer. Initial data from a Phase 2 trial also shows promising efficacy results.
Read more →MAIAMAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
MAIA Biotechnology presented its next-generation telomere-targeting cancer therapies at IRT 2026 in Barcelona. The lead candidate, ateganosine, is designed to selectively damage cancer-cell telomeres while activating immune responses. The company showcased its innovative drug candidates that aim to enhance efficacy through multiple mechanisms, indicating progress in their therapeutic development.
Read more →MAIAMAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology reported promising initial efficacy data from its Phase 2 THIO-101 trial, showing a 90.5% disease control rate in advanced non-small cell lung cancer patients. The trial involved a heavily pre-treated population, and the results are consistent with earlier findings. The combination of ateganosine and cemiplimab demonstrates potential as a third-line therapy, significantly outperforming standard chemotherapy options.
Read more →MAIAMAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
MAIA Biotechnology has completed international enrollment in Part C of its Phase 2 THIO-101 trial, which evaluates ateganosine in advanced non-small cell lung cancer patients. The trial aims to assess the efficacy of ateganosine combined with cemiplimab in patients resistant to previous therapies. The FDA has granted Fast Track designation for ateganosine, potentially expediting its approval process.
Read more →MAIA▲ +6.1%on this news
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
MAIA Biotechnology has opened enrollment for its Phase 2 THIO-101 expansion trial at the Winship Cancer Institute, focusing on ateganosine as a treatment for non-small cell lung cancer. The trial aims to evaluate the efficacy and safety of ateganosine in patients resistant to previous therapies. Early results have shown promising survival rates, indicating potential for this novel agent in addressing unmet medical needs in lung cancer treatment.
Read more →MAIAMAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
MAIA Biotechnology has activated a second U.S. site for its Phase 2 THIO-101 expansion trial, aimed at treating non-small cell lung cancer (NSCLC) with ateganosine. This trial is part of a broader strategy to gather data that may support an accelerated FDA approval. The expansion includes multiple sites across the U.S., Europe, and Asia, enhancing patient enrollment efficiency.
Read more →MAIAMAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA Biotechnology has reported significant progress in its pivotal Phase 3 trial for ateganosine, a novel telomere-targeting therapy for advanced non-small cell lung cancer. With 29 patients dosed across 34 sites in six countries, the company aims to enroll up to 100 patients by year-end. The FDA has granted Fast Track designation for this promising treatment.
Read more →MAIA▲ +5.9%on this newsshared move
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
MAIA Biotechnology has received FDA clearance to expand U.S. enrollment in its Phase 2 THIO-101 trial for ateganosine, targeting advanced non-small cell lung cancer. The trial aims to assess the drug's efficacy in patients who have not responded to previous treatments. The company plans to activate additional clinical sites in the U.S. as part of this expansion.
Read more →MAIAMAIA Biotechnology Announces Open Market Purchases by CEO and Director
MAIA Biotechnology announced that CEO Vlad Vitoc and Director Stan Smith have increased their ownership through open market purchases. Dr. Vitoc purchased approximately 72,700 shares, while Dr. Smith acquired around 75,000 shares. Both executives expressed strong confidence in the company's telomere-targeting immunotherapy, ateganosine, which is in development for advanced non-small cell lung cancer.
Read more →MAIA▼ -6.5%on this newsshared move
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
MAIA Biotechnology presented a poster on its pivotal Phase 3 trial for ateganosine at ASCO 2026. The trial, THIO-104, aims to evaluate the drug's efficacy in treating third-line non-small cell lung cancer (NSCLC) patients resistant to current therapies. The first patient was dosed in December 2025, and enrollment is ongoing in Europe and Asia. The trial seeks to assess ateganosine's effectiveness compared to standard chemotherapy.
Read more →MAIA▼ -6.3%on this news
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology has activated its first U.S. clinical site for the ongoing Phase 2 expansion trial of THIO-101, a novel telomere-targeting treatment for advanced non-small cell lung cancer (NSCLC). The trial aims to evaluate the efficacy of ateganosine, particularly in patients who have previously failed other cancer treatments. Initial findings indicate that this therapy may offer survival outcomes significantly better than current standard of care options. MAIA is set to expand the trial to four additional U.S. sites in 2026, while it is already ongoing in Europe and Asia with 44 active sites across six countries.
Read more →MAIAMAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer
MAIA Biotechnology has successfully raised $33 million through a capital offering, which is anticipated to fully finance its ongoing pivotal Phase 3 trial for ateganosine, a novel therapy aimed at treating non-small cell lung cancer (NSCLC). The company received FDA Fast Track designation for this therapy, which targets telomeres in cancer cells while also activating the immune system. Investor participation reflects strong confidence in the clinical program, with expectations for interim Phase 3 data to potentially support an early approval discussion with the FDA. This pivotal trial is designed to compare ateganosine’s efficacy against standard chemotherapy treatments in patients resistant to previous therapies.
Read more →MAIA▲ +6.9%on this news
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung
MAIA Biotechnology announced promising results from its ongoing Phase 2 THIO-101 clinical trial for patients with non-small cell lung cancer. Eight patients treated with a combination of ateganosine and cemiplimab achieved overall survival rates that exceeded two years, significantly surpassing typical outcomes in their treatment lines. The data was presented at the European Lung Cancer Congress 2026, providing optimism for the future development of ateganosine as a novel immunotherapy agent in the market.
Read more →MAIAMAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
MAIA Biotechnology has successfully closed a public offering of 20 million shares at $1.50 each, raising $30 million. The offering was well-received, with participation from healthcare-focused investors. The funds will be utilized for clinical trials and general corporate needs. Additionally, underwriters have an option to purchase more shares.
Read more →MAIA▼ -27.1%on this newsshared move
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
MAIA Biotechnology has announced the pricing of a public offering of 20 million shares at $1.50 each, aiming to raise $30 million. The offering, which includes a 45-day option for underwriters to purchase additional shares, is set to close on March 4, 2026. Proceeds will be utilized for clinical trials and general corporate needs.
Read more →MAIA▼ -27.1%on this newsshared move
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
MAIA Biotechnology has announced a proposed underwritten public offering of common stock and pre-funded warrants. The company aims to use the proceeds for clinical trials and general corporate purposes. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase additional shares. MAIA's focus remains on developing targeted immunotherapies for cancer.
Read more →About MAIA Biotechnology, Inc.
Headquarters444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606
BIOPHARMAWATCH ELITE PLUS
Trade the next MAIA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime